Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Institute for Oncology and Radiology of Serbia

Source: Site record.

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

The Institute of Oncology and Radiology of Serbia (IORS), located in Belgrade, is a leading public, tertiary-care oncology center in Serbia. As a state-owned institution, it serves as one of the country’s primary hubs for comprehensive cancer care, integrating prevention, diagnosis, treatment, and follow-up within a single system. IORS offers a full spectrum of oncology services, including advanced diagnostic capabilities such as imaging and molecular pathology, along with multidisciplinary treatment approaches. These include medical oncology (chemotherapy, targeted therapy, and immunotherapy) and advanced radiation oncology techniques such as IMRT and stereotactic radiosurgery. The institute works in close coordination with surgical units, enabling holistic cancer management.

Source: Trial-derived.
35Total Trials
Source: Trial-derived.
2Recruiting Trials
Source: Trial-derived.
9Active Trials
Source: Trial-derived.
24Completed Trials
Source: Trial-derived.
42Unique Conditions
Source: Trial-derived.
32Unique Sponsors

Conditions

Source: Trial-derived. Breast Cancer (3)Source: Trial-derived. Early Breast Cancer (2)Source: Trial-derived. Epithelial Ovarian Cancer (2)Source: Trial-derived. Fallopian Tube Cancer (2)Source: Trial-derived. Melanoma (2)Source: Trial-derived. Ovarian Cancer (2)Source: Trial-derived. Small Cell Lung Cancer (2)Source: Trial-derived. Urothelial Cancer (2)

Sponsors

Source: Trial-derived. Hoffmann-La Roche (7)Source: Trial-derived. Pfizer (4)Source: Trial-derived. AbbVie (3)Source: Trial-derived. Puma Biotechnology, Inc. (3)Source: Trial-derived. Gynecologic Oncology Group (2)Source: Trial-derived. Merck Sharp & Dohme LLC (2)Source: Trial-derived. Alliance for Clinical Trials in Oncology (1)Source: Trial-derived. Amgen (1)

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Radiation therapy

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Diagnostic radiologic imaging